Publicacións en colaboración con investigadores/as de Hospital Universitario Central de Asturias (22)

2024

  1. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  2. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

  3. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

2019

  1. Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial (Cancer Chemotherapy and Pharmacology, (2019), 83, 6, (1175-1181), 10.1007/s00280-019-03820-7)

    Cancer Chemotherapy and Pharmacology

  2. Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "sEXSAT-Q"

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

  3. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    BMC Cancer, Vol. 19, Núm. 1

  4. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

    Cancer Chemotherapy and Pharmacology, Vol. 83, Núm. 6, pp. 1175-1181

  5. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

2018

  1. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

2015

  1. Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel

    Future Oncology, Vol. 11, Núm. 2, pp. 267-277

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

  2. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

    Bone, Vol. 68, pp. 32-40

  3. Breast cancer management in the elderly

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 351-361

2013

  1. Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS

    Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121

2011

  1. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

2010

  1. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology